Dana Farber Cancer Institute Dana 1B11 — Boston, Massachusetts

Dana Farber Cancer Institute Dana 1B11 is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute Dana 1B11 has participated in 1 clinical trials.

Therapeutic areas: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD).

Sponsors: Genzyme, a Sanofi Company.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute Dana 1B11?

Dana Farber Cancer Institute Dana 1B11 has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute Dana 1B11 conducted?

Dana Farber Cancer Institute Dana 1B11 has 1 clinical trials on record. Their work covers Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD).

Is Dana Farber Cancer Institute Dana 1B11 accredited by Crixeo Health?

Dana Farber Cancer Institute Dana 1B11 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute Dana 1B11?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.